

PREVENTING HIV TRANSMISSION DURING INFANT FEEDING

Updated: June 25, 2026

Reviewed: June 25, 2026

Panel's Recommendations

- When there is potential for perinatal HIV transmission, evidence-based, patient-centered counseling should be provided to support shared decision-making about infant feeding. Counseling about infant feeding should begin prior to conception or as early as possible in pregnancy; information about and plans for infant feeding should be reviewed throughout pregnancy and again after delivery **(AIII)**. During counseling, inform patients that—
 - Replacement feeding with properly prepared formula or pasteurized donor human milk from a milk bank eliminates the risk of postnatal HIV transmission to the infant through breastfeeding.
 - Achieving and maintaining viral suppression (i.e., <50 copies/ml) through antiretroviral therapy (ART) during pregnancy and postpartum decreases breastfeeding transmission risk to less than 1%, but not zero.
- Replacement feeding with formula or banked pasteurized donor human milk is recommended to eliminate the risk of HIV transmission through breastfeeding when ART is not being taken and/or viral suppression has not been **achieved** during pregnancy (at a minimum throughout the third trimester), as well as at delivery **(AI)**.
- If ART is taken consistently and the viral load is maintained at a level of <50 copies/mL for at least 3 months prior to delivery, counseling about the options of formula feeding, use of banked donor milk, or breastfeeding should be provided. Those who choose to breastfeed should be supported in this decision **(AIII)**.
- If formula feeding is chosen, providers should support this decision. Providers should ask about potential barriers to formula feeding and explore ways to address them **(AIII)**.
- Providers should consider that babies who are breastfed will often require more laboratory monitoring and sometimes additional prophylactic antiretroviral (ARV) medication compared to babies who are formula fed **(BII)** (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#), Table 12. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding, and Table 13. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV in [Diagnosis of HIV Infection in Infants and Children](#)).
- In the case of a detectable viral load (**≥50 copies/mL**) during breastfeeding, breastfeeding should be stopped temporarily or discontinued and replacement feeding initiated while the viral load is rechecked, causes for the viremia are assessed, and, when applicable, adherence counseling is reinforced **(AII)** (see Situations to Consider Stopping or Modifying Breastfeeding later in this section). Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is ≥200 copies/mL **(CIII)**.
 - Depending on the level and persistence of viremia, next steps may include initiating or modifying infant ARV prophylaxis, permanently stopping breastfeeding, and considering the need for additional infant HIV testing (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#), Table 12. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding, and Table 13. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV in [Diagnosis of HIV Infection in Infants and Children](#)).
 - If the repeat parental viral load is **<50 copies/mL**, a joint decision should be made by the parent and providers about whether breastfeeding may resume **(AIII)**.

- Engaging Child Protective Services or similar agencies is not an appropriate response to infant feeding choices impacted by HIV (AIII).
- Clinicians are encouraged to consult the [National Perinatal HIV/AIDS Hotline](#) (1-888-448-8765) with HIV-related questions about infant feeding (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Counseling about infant feeding is an integral component of HIV care during pregnancy and postpartum. Ideally, this counseling should begin before pregnancy, continue during pregnancy, and be reviewed again after delivery. Patient-centered counseling should assess opinions and plans about infant feeding, engage in shared decision-making, and assist in implementing plans for infant feeding. Previously, replacement feeding with properly prepared formula or banked, pasteurized donor human milk was recommended as the only option for infant feeding in the United States for infants perinatally exposed to HIV because it is generally available and eliminates any risk of HIV transmission through breastfeeding. However, breastfeeding provides certain benefits to the breastfeeding dyad that are not possible with formula feeding. In addition, the risk of transmission through breastfeeding is very low, but not zero, for women on antiretroviral therapy (ART) with a sustained HIV viral load <50 copies/mL.¹⁻⁴

The Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (the Panels) recommend that clinicians engage parents in patient-centered counseling and shared decision-making regarding infant feeding. As part of this process, providers and parents should discuss both replacement feeding and breastfeeding and address the possible use of infant antiretroviral (ARV) prophylaxis during breastfeeding in addition to the ARV prophylaxis recommended for all infants with perinatal HIV exposure. (see [Table 12. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding](#) and [Table 12.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed in Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). Counseling should also address issues related to breast health (e.g., mastitis), mixed feeding, visit frequency, and laboratory monitoring during breastfeeding and weaning.

Panel recommendations are in line with the American Academy of Pediatrics and the opinions of multiple experts and community organizations that have called for a patient-centered approach to infant feeding decision-making.⁴⁻¹³ Other countries have updated their guidelines for management of breastfeeding in the context of HIV: Switzerland in 2018,¹⁴ Australia in 2021,¹⁵ Canada in 2023,¹⁶ and the United Kingdom in 2025.¹⁷ All countries named have moved in the direction of less restrictive and more supportive care for breastfeeding infants with perinatal HIV exposure.

Surveys of pediatric infectious disease specialists and neonatologists in the United States demonstrate wide heterogeneity in uptake of the current infant feeding guidelines and variability in key practices, with a focus on concern about any potential residual risk for HIV transmission and a high degree of risk aversion among these subsets of U.S. clinicians.^{18,19} Qualitative studies in high-resource settings have identified that clinicians need to be cognizant that the decision to breastfeed is not solely based on the risk of HIV transmission. Health benefits to the infant, bonding, and meeting cultural expectations have been articulated by women who have chosen to breastfeed.²⁰ Specific barriers to breastfeeding (e.g., frequent testing of mother and infant, risk of transmission, and lack of confidence to breastfeed) as well as facilitators (e.g., advantages of breastmilk, availability of a lactation consultant, and peer support) need to be addressed.²¹ European reports have shown that only 50% of European countries surveyed support breastfeeding among women

with HIV, which has led to women receiving mixed messages about the feasibility of breastfeeding in the context of maternal HIV.²²⁻²⁴

Most of the data on HIV transmission via breast milk comes from studies conducted in low- and middle-income countries. However, there is growing interest in breastfeeding by people with HIV and health care providers in the United States and other higher-income countries. Data about breastfeeding with HIV in these settings are limited but have been explored in a number of studies. Ten observational studies have reported on groups of 7 to 77 breastfeeding infants estimated to reflect a total of 184 to 214 unique infants in Germany,^{25,26} Italy,²⁷ Switzerland,¹⁴ and the United States and Canada.²⁸⁻³² In these publications, participants who breastfed were on ART, generally started before or in the first trimester of pregnancy, and were documented to be virally suppressed (viral load <50 copies/mL to <400 copies/mL) at the time of delivery and/or in late pregnancy. A few cases of low-level viremia were reported postpartum, with cessation of breastfeeding in most instances. Infant ARV prophylaxis varied within and across study locations, including no ARV prophylaxis, zidovudine (ZDV) and/or nevirapine (NVP) for 2 to 6 weeks after birth, or continuing prophylaxis through 1 month after weaning. Some centers chose therapeutic dosing with three-drug ARV regimens for either the first 4 to 6 weeks after birth or through weaning. Although none of the studies identified cases of HIV transmission related to breastfeeding, the studies were not designed to evaluate transmission (see the subsection on Risk of HIV Transmission to Infants Through Breastfeeding below), the number of participating infants was small, and follow-up has not been completed for all participants. A case of breastfeeding HIV transmission reported in 2024 occurred in a mother–infant dyad who had been lost to follow up after the 1-month postpartum visit; the mother had a viral load more than 5,000,000 copies/mL once reconnected to care when the baby was 17 months of age.³² Challenges during breastfeeding—including mastitis, inadequate milk supply with need for formula supplementation, episodes of detectable viral load, and difficulty weaning—require further study to inform optimal management.

Clinicians who provide HIV care who have questions about infant feeding or are considering breastfeeding are encouraged to consult with an expert and/or the [National Perinatal HIV/AIDS Hotline](https://www.hivhotline.org/) (1-888-448-8765).

Overview of Counseling and Management

If ART is taken consistently and the viral load is maintained at a level of <50 copies/mL for at least 3 months prior to delivery, the Panels recommend counseling about the options of formula feeding, banked donor milk, or breastfeeding and supporting infant feeding decisions.

When ART is not being taken and/or a suppressed viral load is not achieved at delivery, replacement feeding with formula or banked pasteurized donor human milk is recommended to eliminate the risk of HIV transmission. However, it is important to recognize that accessing an adequate supply of formula may be difficult sometimes, and there may be cost and access barriers to obtaining donor milk. For anyone with HIV who chooses replacement feeding, systems of care should ensure supportive access to clean water, safe formula, and banked human milk, if available.

A number of institutions in the United States have developed their own protocols for counseling and providing HIV care when there is an interest in breastfeeding.^{28,33-35} Although these country guidelines and institution-level protocols have some differences, they all entail common elements: standardized counseling regarding infant feeding options during HIV care, a multidisciplinary team-based approach, lactation support, adherence counseling and support, and close monitoring of the breastfeeding dyad.¹⁷ Approaches to infant prophylaxis are quite variable (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). In a provider

survey conducted in 2021, institutional protocols supporting breastfeeding with HIV were rare but were associated with higher degrees of provider comfort when patients chose to breastfeed.³⁶

Special Concerns

Engaging Child Protective Services or similar agencies is not an appropriate response to infant feeding choices impacted by HIV.

There have been numerous reports that after a patient expressed interest in or intention to breastfeed, providers threatened to make a report to Child Protective Services or actually did so. Such engagements can be extremely harmful to families, can exacerbate the stigma and discrimination associated with HIV, and are disproportionately applied to lower-income families and Black and Indigenous children.³⁷⁻³⁹

Other Considerations

Counseling about infant feeding options, as discussed in this section, should be provided to all pregnant patients impacted by HIV. Patients should be asked nonjudgmental questions about their self-expression, including how they want to be referred to as a parent (e.g., mother, father, another name), and how they want to describe infant feeding (e.g., breastfeeding, another name). For patients taking testosterone before pregnancy, there are no evidence-based guidelines on the timing of restarting it after giving birth or while breastfeeding. In one published case report of restarting testosterone 13 months postpartum while still lactating, the calculated milk-to-plasma ratio was under 1.0, the calculated relative infant dose was under 1%, the infant had no observable side effects, and the infant serum testosterone concentrations remained undetectable.⁴⁰

Approach to Counseling

Health care providers who provide HIV care during pregnancy or prepregnancy should initiate conversations about infant feeding early in pregnancy, or prior to the pregnancy, and the discussion should continue during the pregnancy.²¹

One approach is to say, “Have you thought about how you would like to feed your baby? Formula feeding eliminates the risk of HIV transmission through breast milk. Less than 1 of 100 breastfed infants would be expected to acquire HIV through breast milk when ART is being taken and a sustained undetectable viral load is achieved while lactating; however, the risk is not zero. What information can I provide to help you decide?”

When breastfeeding with HIV is being considered, providers should engage in patient-centered, evidence-based counseling about infant feeding, allowing for shared decision-making. It should be a private, nonjudgmental conversation to understand the motivations for breastfeeding (e.g., bonding, health benefits for the breastfeeding dyad) and potential barriers to formula feeding (e.g., concern about formula feeding inadvertently disclosing HIV status, barriers to accessing formula, cultural concerns). Factors such as resource accessibility, the need for informed lactation support, and history of medication adherence should be considered when making these decisions. The conversation should also include information about the risks of HIV transmission during breastfeeding, the importance of sustained viral suppression, and common challenges to ART adherence during the postpartum period.

People with HIV desire to be counseled about safe infant feeding practices and have their questions answered without judgment.^{33,41} Community-based organizations have developed patient-facing materials to assist with decisions around infant feeding options during pregnancy.⁴² When the choice is made to breastfeed, counseling should include the importance of adherence to ART, sustained

viral suppression during pregnancy and breastfeeding, and engagement in postpartum care. Points to address are listed below:

- The infant feeding options that eliminate the risk of HIV transmission are formula and pasteurized donor human milk.
- Fully suppressive ART during pregnancy and breastfeeding decreases breastfeeding transmission risk to less than 1%, but not zero.
- When ART for HIV is being taken with a sustained viral load **<50 copies/mL**, counsel about the options of formula feeding, use of banked donor milk, or breastfeeding. Those who choose to breastfeed should be supported in this decision.
- For those who choose to breastfeed, exclusive breastfeeding (no formula or other foods) through the first 6 months is recommended. It is important to acknowledge that there may be intermittent need to give formula (e.g., infant weight loss, milk supply not yet established, not having enough stored milk, transient increases in viral load). **There is no evidence that formula supplementation increases the risk of HIV acquisition in the breastfed infant in the context of parental ART and viral suppression.**
- The postpartum period, which can be difficult for all parents, can present several challenges to medication adherence and engagement in care. Ensuring that parents have access to both a supportive clinical team and peer support in the postpartum period is beneficial in promoting medication adherence and viral load monitoring (see [Postpartum HIV Management and Follow-Up](#)).
- Access to a provider who is a breastfeeding specialist certified by the Academy of Breastfeeding Medicine (when available) or a lactation consultant with expertise in supporting breastfeeding with HIV is beneficial.
- Breastfeeding provides numerous **maternal** health benefits, such as reduction in hypertension, type 2 diabetes, and breast and ovarian cancers, and benefits for the breastfed infant, such as reduction in asthma, gastroenteritis, and otitis media.⁴³

Because infant feeding management spans multiple health care settings and providers/teams, it is important that clear documentation that reflects the shared decision-making process and counseling can be accessed by all providers. Some providers and/or institutions have chosen to require a signed form acknowledging the counseling provided; others have felt this practice is too stigmatizing and prefer to document the infant feeding discussion in the patient's chart without requiring a signed form.³⁴

Approach to Management

If the decision is made to breastfeed, several measures should be taken to reduce the possibility of HIV transmission. Ideally, care of the breastfeeding dyad should be coordinated prior to delivery among the maternity care provider, HIV provider, infant provider, breastfeeding specialist certified by the [Academy of Breastfeeding Medicine](#) (when available), lactation consultant, and social worker, all of whom may need education about new approaches to infant feeding with HIV.^{16,28,33-36} **Many settings do not have access to all of the recommended ancillary services—this should not limit the option for patients to breastfeed.** Recommendations for management include the following:

- Support ART adherence and engagement in care throughout pregnancy and breastfeeding.
 - Provide case management and/or social work support from individual(s) with perinatal support experience.

- o Ensure continued access to ARV medications throughout the breastfeeding period, recognizing that patients may have changes to insurance status and may need support applying for assistance programs.
- o Provide early active referral to a supportive lactation consultant, preferably a breastfeeding medicine provider when available, beginning prenatally or at delivery and continuing until breastfeeding is well established. The lactation consultant should be knowledgeable in concerns regarding HIV transmission and the situations in which to consider stopping or temporarily interrupting breastfeeding. (Refer to the next section on Situations to Consider Stopping or Modifying Breastfeeding.)
- o Screen and provide support for postpartum depression and other mental health conditions that are highly prevalent after giving birth and may affect ART adherence. Postpartum depression occurs more frequently with HIV compared to without HIV⁴⁴ (see [Postpartum HIV Management and Follow-Up](#)).
- Document sustained viral suppression before delivery and throughout breastfeeding.
 - o No data exist to inform the appropriate frequency of **maternal** viral load testing while breastfeeding. One approach is to monitor the plasma viral load of the parent every 1 to 2 months during breastfeeding.^{29,45}
 - o Decide which clinician (e.g., prenatal care provider or primary care HIV clinician) is responsible for following viral loads of the parent postpartum and continuing counseling/education around breastfeeding.
 - o If viral load becomes detectable (≥ 50 copies/ml) during breastfeeding, the Panels recommend that breastfeeding be temporarily stopped or discontinued and replacement feeding initiated (see Situations to Consider Stopping or Modifying Breastfeeding below). There are no data that clearly define a specific viral load threshold for permanent discontinuation of breastfeeding. Most experts recommend permanent discontinuation of breastfeeding when viral load is ≥ 200 copies/mL. Guidance about infant ARV management when viremia develops during breastfeeding is provided in Antiretroviral Prophylaxis for Infants Exposed to Detectable HIV RNA During Breastfeeding in [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#); see [Table 12. Antiretroviral Management of Infants With Exposure to HIV or Exposure During Breastfeeding](#) and [Table 12.1 Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed](#).
- Recommend exclusive breastfeeding in the first 6 months of life, followed by the introduction of complementary foods (e.g, solids) with continued breastfeeding, if desired.⁴³ Some parents may choose to stop breastfeeding and switch to formula prior to 6 months of age.
 - o Provide support for exclusive breastfeeding, acknowledging that there may be scenarios where formula supplementation is needed. There is no evidence that formula supplementation increases the risk of HIV acquisition in the breastfed infant in the context of parental ART and viral suppression. In pre-ART studies, exclusive breastfeeding was associated with lower rates of HIV transmission compared to mixed feeding (a term used to describe infants fed breast milk plus other liquid or solid foods, including formula).^{46,47} The highest risk in these studies was from very early introduction of solids (before 2 months of age).^{46,48} Whether this remains a risk factor when viral suppression is sustained during breastfeeding has not been studied. There is no data to guide switching to breastmilk after a period of formula feeding, so patient-centered decision making is key in these unique situations. Notably these women often require significant lactation support to obtain a supply adequate to support exclusive feeding.

- o If supplementation is needed during a hospital stay, prioritize the use of pasteurized donor human milk when feasible, recognizing that this will not be an option in all scenarios and should not limit the ability of parents to choose to breastfeed.
- Administer appropriate ARV prophylaxis starting at birth; see Antiretroviral Prophylaxis for Breastfeeding Infants, [Table 12. Antiretroviral Management of Infants With Exposure to HIV or Exposure During Breastfeeding](#) and [Table 12.1 Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed in Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#).
- Provide guidance on good breast care, including strategies to avoid and promptly resolve overproduction of breast milk, milk stasis, and breast engorgement, which can lead to sore nipples, mastitis, or breast abscess. Promptly identify and treat mastitis, thrush, and cracked or bleeding nipples. These conditions may increase the risk of HIV transmission through breastfeeding, although the impact of these conditions in the context of ART and viral suppression is unknown.⁴⁹
- Develop a joint plan for weaning with family and providers. Since very rapid weaning was associated with increased risk of HIV shedding into breast milk and risk of transmission in the pre-ART era,⁵⁰⁻⁵² weaning over a 2- to 4-week period might be safer, paying special attention to good breast care and avoidance of breast engorgement and milk stasis.
- There is little evidence to guide the infant HIV testing schedule during breastfeeding. Information about HIV testing for infants who are being breastfed is available in [Diagnosis of HIV Infection in Infants and Children](#) (see [Table 13. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#)).

Situations to Consider Stopping or Modifying Breastfeeding

Situations may arise in which there is a need to temporarily stop or discontinue breastfeeding and initiate replacement feeding, such as a detectable viral load or developing mastitis or bleeding nipples during breastfeeding. If the situation is temporary, some options to consider while expressing breast milk until the condition has resolved or viral load becomes undetectable (<50 copies/mL) include: (1) giving previously stored expressed milk from a date when viral suppression was achieved while encouraging pumping and discarding breast milk to ensure that breastfeeding can resume; (2) pumping and flash heating breast milk before feeding it to the infant; (3) providing replacement feeding with formula or pasteurized donor human milk while encouraging pumping and discarding breast milk to ensure that breastfeeding can resume; or (4) permanently stopping breastfeeding. Flash heating, which has been documented to eliminate HIV from breast milk, involves placing a sample of milk in a glass container within a small pot of water, heating the water to a boil, and immediately removing the milk from the heated water when the water has boiled.^{53,54} Once cooled to room temperature, milk can be given to the infant via bottle or cup.

In the case of mastitis or bleeding nipples, pump and either flash heat or discard milk from the affected breast while continuing to feed or pump from the unaffected breast, at least until symptoms resolve. Patients should express milk at a frequency and volume that mimics physiological breastfeeding to avoid overstimulation of milk production.⁵⁵ In the pre-ART era, mastitis was associated with an increased risk of lactational transmission of HIV.⁵⁶ Elevated breast milk HIV RNA during episodes of mastitis has been shown to be an important factor that contributes to this increased risk of transmission.⁵⁷ In a longitudinal cohort of 38 breastfeeding women with HIV who developed mastitis or abscess, significant increases in breast milk HIV RNA were observed in the affected breast and decreased back to the baseline level or lower with symptom resolution. In the contralateral (or unaffected) breast, breast milk HIV RNA did not change over the period of mastitis. The increase in breast milk HIV RNA was more marked in women with abscess or a greater number of mastitis symptoms.⁵⁸ This finding supports the Panels' recommendation that women with HIV with

mastitis or other unilateral breast pathology stop breastfeeding on the affected breast and feed on the contralateral breast; once symptoms resolve, women can again feed from both breasts. It is unknown how, or if, mastitis impacts the risk of lactational HIV transmission in the context of ART and viral suppression, although one study did show that mastitis was associated with postnatal transmission only when maternal plasma HIV load was high.⁵⁹

In the case of a viral load that becomes detectable (≥ 50 copies/mL) while breastfeeding, the Panels recommend temporarily stopping or discontinuing breastfeeding and initiating replacement feeding, using one of the options described above, engaging in shared decision-making, assessing the etiology of the viremia, and repeating the viral load. Due to the risk of postnatal transmission associated with viremia during breastfeeding, the Panels advise immediate cessation of breastfeeding if viral load becomes detectable; this guidance is more directive than counseling when ART is being taken with sustained viral suppression. Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is ≥ 200 copies/mL. The exact association between degree and duration of viremia and lactational transmission is not known. In situations where viremia is low and an addressable cause has been identified, the added risk of short-term continued breastfeeding until a repeat viral load is available is likely to be low.

Any viremia is an opportunity to review the risks and benefits of continued breastfeeding, adherence strategies, and other considerations, such as ARV prophylaxis for the breastfeeding infant (see [Table 12. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding](#) and [Table 12.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed in Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). If the repeat viral load is < 50 copies/mL, a joint decision should be made by the parent and the clinician about whether breastfeeding may resume. If the repeat viral load remains detectable (≥ 50 copies/mL), support should be provided to continue replacement feeding.

The [Diagnosis of HIV Infection in Infants and Children](#) section provides guidance about HIV diagnostic testing for infants who are being breastfed. If, after counseling, the choice is made to continue breastfeeding with viremia, the parent and provider should remain engaged; the provider should offer guidance on ARV prophylaxis and testing for the infant and assist the parent to rapidly regain and maintain virologic suppression. Consultation with an expert or the [National Perinatal HIV/AIDS Hotline](#) (1-888-448-8764) is recommended.

Infant HIV Infection

If an infant has a positive virologic assay (HIV RNA or HIV DNA nucleic acid test), it should be confirmed as soon as possible with a repeat virologic test (see [Diagnosis of HIV Infection in Infants and Children](#)). Antigen–antibody combination immunoassays are not recommended for diagnosis in infants because of the transplacental transfer of HIV antibodies during pregnancy.

In the event of HIV transmission via breastfeeding, consult a pediatric HIV specialist and promptly initiate a full ART regimen for the infant (see [What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children With HIV](#) in the [Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection](#)). Infants with confirmed HIV can breastfeed.

Factors Affecting Decisions About Infant Feeding

Several factors affect parents' decisions about infant feeding. Patient-centered counseling should be conducted in a manner that supports the family by sharing the risks and benefits of feeding options; listening to beliefs, values, and interests of parents; addressing concerns; and engaging in shared decision-making to identify and support each family's infant feeding decision.

Benefits of Breastfeeding

In general, breastfeeding is widely considered to be the healthiest infant feeding option for both parents and infants in the general population (see the Centers for Disease Control and Prevention [Breastfeeding Fast Facts](#)). Breastfeeding is associated with improved neonatal immune status and a lower risk of infants developing asthma, obesity, type 1 diabetes, severe lower respiratory disease, otitis media, sudden infant death syndrome, gastrointestinal infections, and necrotizing enterocolitis. In Kenya, a comparison of infants who were HIV-exposed and uninfected to infants who were HIV-unexposed and uninfected showed no difference in growth and development between the two groups, but breastfeeding was associated with improved growth and development scores in both groups.⁶⁰ In addition to bonding with infants and avoiding the monetary costs of formula, maternal benefits to breastfeeding include decreased risk of hypertension; type 2 diabetes; and breast, endometrial, and ovarian cancers.⁴³ An exclusive focus on the risk of perinatal HIV transmission via breastfeeding fails to acknowledge the health benefits of lactating and the health benefits that may be lost by prohibiting breastfeeding with HIV.

Access Considerations

Black women are disproportionately affected by HIV. People of color and their infants also experience a greater burden of many health conditions that research has shown may be alleviated by breastfeeding.⁶¹ These outcomes are largely driven by the effects of structural racism, poverty, and segregation. Research has also shown that systemic racism contributes to lower uptake and continuation of breastfeeding among Black individuals without HIV.⁶² These issues should be considered as part of counseling and support for decisions around infant feeding with HIV in the United States. It is also important to recognize that, even in the United States, some people have limited access to safe water and/or difficulty obtaining formula. It is estimated that 17% of the U.S. population relied on privately owned wells for water in 2010; these are not regulated and are not subject to Environmental Protection Act standards.⁶³

Cultural Considerations

Environmental, social, familial, and personal pressures to consider breastfeeding may be faced during pregnancy.^{5,12,61,64-69} Many factors affect a woman's decision to breastfeed her infant; these include bonding; maternal and infant health benefits; social, cultural, and religious factors; and concerns about HIV-related stigma and disclosure.^{14,31,65}

Some women, especially those from a country or cultural background where breastfeeding is the norm, fear that not breastfeeding will lead to disclosure of their HIV status.^{5,68,69} Focus groups held in Canada elucidated the importance of discussing infant feeding options and motivations to breastfeed, especially among women who had immigrated from other countries where they had been encouraged to breastfeed.¹³

Risk of HIV Transmission to Infants Through Breastfeeding

Both the evidence regarding the risk of HIV transmission via breastfeeding and the strategies to reduce this type of transmission come from studies conducted in low- and middle-income countries, where rates of infant mortality are high and many families do not have access to safe water and affordable formula. Without maternal ART or infant ARV prophylaxis, the risk of an infant acquiring HIV through breastfeeding is 15% to 20% over 2 years.^{70,71} The mechanisms of HIV transmission by breastfeeding are not fully understood.^{72,73} This lack of current knowledge, and the fact that rare HIV transmissions during breastfeeding have occurred when breast milk and/or plasma HIV viral load was <50 copies/mL, complicate decision-making.^{74,75} Maternal plasma HIV tends to correlate with

breastmilk cell-free HIV RNA. Breastmilk cell-associated HIV DNA may persist despite suppressed maternal plasma HIV RNA, but may be replication incompetent.⁷⁶ Predictors and characterization of breastmilk cell-associated HIV DNA and its potential link to HIV transmission through breastmilk need further study.

A systematic review and meta-analysis published in 2025 identified 13 studies that provided estimates of postnatal transmission rates stratified by most recent maternal viral load. The monthly risks of transmission while breastfeeding were 0.1% (95% confidence interval [CI], 0.0–0.2) with a recent maternal viral load of <50 copies/mL and 0.3% (95% CI, 0.0–1.8) with a recent maternal viral load ≥50 copies/mL.⁷⁷ This paper provided a significant update to a systematic review and meta-analysis published in 2017 that identified six studies with ART started at some point during pregnancy and continued for at least 6 months postpartum that provided estimates of postnatal transmission rates. The pooled postnatal transmission rate at 6 months was 1.1% (95% CI, 0.32% to 1.85%), with substantial heterogeneity. Transmission rates in the included studies ranged from 0.2% to 3.1%.⁷⁸

Studies have shown that maternal ART throughout pregnancy and breastfeeding or infant ARV prophylaxis during breastfeeding can reduce, but **may** not eliminate, the risk of breast milk–associated HIV transmission.^{79–83} However, in most of these studies, ART was initiated late in pregnancy, and ARV medications for women or infants were only provided for 6 months after birth, with limited data on maternal plasma HIV viral load during breastfeeding.

As ART has become more widely available for women during pregnancy and the postpartum period, studies have evaluated HIV transmission during breastfeeding among women who continued ART longer than women in previous studies. The PROMISE (Promoting Maternal and Infant Survival Everywhere Study) trial, which included more than 2,400 women with CD4 T lymphocyte cell counts ≥350 cells/mm³, compared the efficacy of prolonged infant ARV prophylaxis with daily oral NVP to maternal ART in preventing HIV transmission during breastfeeding. Both treatments continued through cessation of breastfeeding or 18 months postpartum, whichever came first. This study reported estimated transmission rates of 0.3% at 6 months and 0.6% at 12 months in both arms.¹ Both maternal HIV RNA load and maternal HIV drug resistance were independently associated with breastfeeding transmission.⁸⁴ A secondary analysis of the PROMISE trial demonstrated an association between maternal viral load and HIV transmission among mother–baby pairs in the maternal ART arm but not in the infant ARV prophylaxis arm. Two infants in the maternal ART arm acquired HIV despite maternal viral load measured as not detected or detected but less than 40 copies/mL on the date that the infants' first samples tested positive for HIV RNA.⁷⁴

Smaller studies have also looked at HIV transmission in the context of maternal ART and viral load monitoring. Two cases of HIV transmission during breastfeeding were reported among 186 infants born during a study in Tanzania; the first occurred in the infant of a mother who had a high viral load 1 month after delivery, and the second occurred after a mother discontinued ART. No cases of HIV transmission were reported among infants who were born to virally suppressed mothers who remained in care.⁸⁵

In a prospective follow-up of 475 breastfeeding mother–infant pairs in Zimbabwe, there were two postpartum transmissions, both from women with HIV RNA levels >1,000 copies/mL.⁸⁶ In a secondary analysis of the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study, increased maternal ART adherence was associated with lower breast milk and plasma viral loads. Higher breast milk and plasma viral loads were associated with increased breast milk transmission. When maternal plasma viral load remained <100 copies/mL during breastfeeding, there were no occurrences of infant HIV acquisition.⁷⁵

There have been at least six additional published cases of HIV transmission when maternal viral load was <50 copies/mL close to the time of transmission. Two cases are from an observational

study in Malawi. In one, ART was started 8 weeks before delivery, and maternal plasma RNA was <37 copies/mL at 1 month, 3 months, 6 months, and 12 months postpartum. The infant was breastfed until 9 months of age and tested positive for HIV at 12 months of age after testing negative at Months 1, 3, and 6. HIV RNA measured in the breast milk was 293 copies/mL at 1 month postpartum and <37 copies/mL at Months 3 and 6. In the second case, ART was started 14 weeks before delivery, and maternal plasma RNA was <37 copies/mL at 1 month and 3 months postpartum. The infant tested positive for HIV at 3 months of age, after testing negative at 1 month. HIV RNA measured in the breast milk was <37 copies/mL at 1 month postpartum and 90 copies/mL at 3 months.⁸⁷

The Mma Bana study in Botswana compared triple nucleoside reverse transcriptase inhibitor (NRTI) therapy (abacavir, ZDV, and lamivudine [3TC]) to protease inhibitor (PI)-based therapy (lopinavir/ritonavir plus ZDV and 3TC). There were two lactational transmissions where maternal plasma and breast milk RNA were <50 copies/mL at 1 and 3 months postpartum, both in the NRTI arm. In one case, ART was started 4 weeks before delivery and viral load was elevated at delivery; the infant tested positive for HIV at 94 days of life after testing negative at 28 days. In the other case, ART was started 14 weeks before delivery and HIV RNA was <50 copies/mL at delivery, although issues with adherence were reported; the infant tested positive for HIV at 91 days of life after testing negative at 21 days.⁸⁸ In DOLPHIN-2 (Dolutegravir in Pregnant HIV Mothers and Their Neonates), which compared dolutegravir- versus efavirenz (EFV)-based ART started in the third trimester, out of 268 mother–infant pairs, there was one breastfeeding HIV transmission in the EFV group. HIV was diagnosed in the infant at 72 weeks of age (16 months), and maternal viral load was <50 copies/mL at 12 weeks, 24 weeks, 48 weeks, and 72 weeks postpartum.^{1,2,74,84} The VESTED study had one transmission in the context of maternal viral suppression. ART was started at 22 weeks gestational age. The mother had persistent low-level viremia (range 5–323 copies/mL) during breastfeeding and no HIV drug resistance through 26 weeks postpartum, after which her viral load suppressed to <50 copies/mL. The infant tested HIV DNA negative on five dates between the ages of 1.6 and 38.6 weeks but tested HIV DNA positive at the age of 59.7 weeks with resistance mutations (M184V/I and Y188L).^{89,90}

In all these studies, maternal ART was initiated in the second or third trimester or postpartum. No studies have systematically evaluated the risk of HIV transmission through breastfeeding when maternal ART is started before pregnancy or in the first trimester and continued throughout breastfeeding.

In the Tshilo Dikotla Study (Botswana), frequent monitoring of HIV viral load occurred in pregnancy and postpartum while breastfeeding was ongoing, counseling was offered on adherence to ARV medications for both mothers and infants, and infant virologic diagnostic tests were performed routinely. Women were maintained on ART, and infants received 4 weeks of prophylactic ZDV or NVP. If a woman had a viral load ≥ 40 copies/mL, she was encouraged to switch to formula feeding, but shared decision-making was employed. Among 247 participants, 19 had viral loads ≥ 40 copies/mL at some point during breastfeeding. Twelve chose to stop breastfeeding, and seven continued to breastfeed with ongoing counseling and frequent viral load checks. There were no cases of HIV transmission via breastfeeding.⁹¹

Safety of Antiretroviral Drugs During Breastfeeding

Parents are often concerned about infant exposure to ARV medications through breast milk. Although data are limited, no ARVs are contraindicated for use during lactation, including newer agents, such as long-acting ARVs.

The non-nucleoside reverse transcriptase inhibitors (NNRTIs) NVP, EFV, and etravirine have been detected in breast milk; however, the levels of these ARV medications that have been detected in breast milk are lower than those seen in maternal plasma. Among PIs, lopinavir, ritonavir, and atazanavir have been found in very low concentrations in breast milk, with little to no drug detectable in the blood of the breastfed infant.⁹² NRTIs show more variability than PIs and NNRTIs. Tenofovir concentrations from tenofovir disoproxil fumarate (TDF) are very low in breast milk, and the drug is undetectable in the blood of the breastfed infant.⁹²⁻⁹⁴ Emtricitabine and 3TC have more accumulation in breast milk and can sometimes be detected in the blood of the breastfed infant (in 19% and 36% of infants, respectively).⁹² A subanalysis of the BAN study confirmed higher levels of the NRTIs ZDV and 3TC in breast milk than in maternal plasma, in contrast to NNRTIs and PIs. The study demonstrated that higher drug concentrations in the maternal plasma and breast milk compartments were associated with lower levels of the virus in both compartments and a lower incidence of viral transmission during breastfeeding.⁹⁵ Data on the transfer of integrase strand transfer inhibitors to breast milk in humans are limited; data do show that dolutegravir is found in breast milk at levels that are about 3% of those seen in maternal plasma.⁹⁶ For more details on the passage of ARV medications into breast milk, see the individual drug sections in [Appendix B: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy](#).

A systematic data review showed a decrease in maternal bone mineral content among breastfeeding mothers who were receiving TDF-based ART compared to mothers who received no ART, but whether this persisted after discontinuation of breastfeeding was not known.⁹⁷ The clinical significance of the reduced bone mineral density is uncertain. Subsequent studies in Africa have shown TDF-based ART to be associated with a decrease in bone mineral density during lactation. In one study, bone mineral density decline through 74 weeks postpartum was greater in breastfeeding women with HIV receiving TDF than in those receiving ZDV-based ART.⁹⁸ A second study comparing bone mineral density in women with HIV receiving TDF-based ART to women without HIV showed accelerated loss during lactation, with only partial recovery by 3 months after cessation of lactation.⁹⁹

The rates of serious adverse events among infants who receive ARV prophylaxis during breastfeeding are low (see Safety of Antiretroviral Drugs for Infant Prophylaxis in [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#)).

Knowledge Gaps

- Further evaluation is needed on the significance, prevalence, and replication competence of cell-associated DNA in breast milk in the context of suppressed maternal plasma HIV RNA to help better understand the risk of HIV transmission with a suppressed viral load and potentially help elucidate the role of infant prophylaxis.
- Research is needed on breastfeeding in the context of maternal ART; future studies should include babies who are receiving both breastmilk and formula and evaluate the impact, if any, on the risk of HIV transmission.
- Implementation research is needed to evaluate how the guidelines on infant feeding developed by the Panels are being implemented in various settings across the United States. These findings will highlight opportunities to provide targeted education and support, especially among non-HIV specialists.

References

1. Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. *J Acquir Immune Defic Syndr*. 2018;77(4):383-392. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239901>.
2. Malaba TR, Nakatudde I, Kintu K, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. *Lancet HIV*. 2022;9(8):e534-e543. Available at: <https://pubmed.ncbi.nlm.nih.gov/35905752>.
3. Behrens GMN, Aebi-Popp K, Babiker A. Close to zero, but not zero: what is an acceptable HIV transmission risk through breastfeeding? *J Acquir Immune Defic Syndr*. 2022;89(4):e42. Available at: <https://pubmed.ncbi.nlm.nih.gov/34897228>.
4. Abuogi L, Noble L, Smith C, Committee on Pediatric and Adolescent HIV; Section on Breastfeeding. Infant feeding for persons living with and at risk for HIV in the United States: clinical report. *Pediatrics*. 2024;153(6):e2024066843. Available at: <https://pubmed.ncbi.nlm.nih.gov/38766700>.
5. Yudin MH, Kennedy VL, MacGillivray SJ. HIV and infant feeding in resource-rich settings: considering the clinical significance of a complicated dilemma. *AIDS Care*. 2016;28(8):1023-1026. Available at: <https://pubmed.ncbi.nlm.nih.gov/26881474>.
6. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. *Lancet*. 2021;396(10267):1994-2005. Available at: <https://pubmed.ncbi.nlm.nih.gov/33308425>.
7. Morrison P, Israel-Ballard K, Greiner T. Informed choice in infant feeding decisions can be supported for HIV-infected women even in industrialized countries. *AIDS*. 2011;25(15):1807-1811. Available at: <https://pubmed.ncbi.nlm.nih.gov/21811145>.
8. Johnson G, Levison J, Malek J. Should providers discuss breastfeeding with women living with HIV in high-income countries? An ethical analysis. *Clin Infect Dis*. 2016;63(10):1368-1372. Available at: <https://pubmed.ncbi.nlm.nih.gov/27572099>.
9. Kahlert C, Aebi-Popp K, Bernasconi E, et al. Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting? *Swiss Med Wkly*. 2018;148:w14648. Available at: <https://pubmed.ncbi.nlm.nih.gov/30044473>.
10. British HIV Association. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update). 2020. Available at: <https://bhiva.org/wp-content/uploads/2024/10/BHIVA-Pregnancy-guidelines-2020-3rd-interim-update.pdf>
11. Gostin LO, Kavanagh MM. The ethics of breastfeeding by women living with HIV/AIDS: a concrete proposal for reforming department of health and human services recommendations. *J Law Med Ethics*. 2019;47(1):161-164. Available at: <https://pubmed.ncbi.nlm.nih.gov/30994078>.
12. Well Project Expert consensus Statement [press release]. 2020.

13. Khan S, Kennedy VL, Loutfy M, et al. “It’s not easy”: infant feeding in the context of HIV in a resource-rich setting: strengths, challenges and choices, a qualitative study. *J Assoc Nurses AIDS Care*. 2021;32(1):105-114. Available at: <https://pubmed.ncbi.nlm.nih.gov/33177433>.
14. Crisinel PA, Kusejko K, Kahlert CR, et al. Successful implementation of new Swiss recommendations on breastfeeding of infants born to women living with HIV. *Eur J Obstet Gynecol Reprod Biol*. 2023;283:86-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/36801775>.
15. Allan B, Machon KE (eds). The optimal scenario and context of care. ASHM guidance for healthcare providers regarding infant feeding options for people living with HIV with highlights from breastfeeding and women living with HIV in Australia. The Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine. 2021. Available at: https://ashm.org.au/wp-content/uploads/2022/04/Resource_ASHM-HIV-Infant-feeding-Guidance_FINAL.pdf.
16. Khan S, Tsang KK, Brophy J, et al. Canadian Pediatric & Perinatal HIV/AIDS Research Group consensus recommendations for infant feeding in the HIV context. *J Assoc Med Microbiol Infect Dis Can*. 2023;8(1):7-17. Available at: <https://pubmed.ncbi.nlm.nih.gov/37008587>.
17. British HIV Association. BHIVA guidelines on the management of HIV in pregnancy and the postpartum period. 2025. Available at: <https://bhiva.org/clinical-guideline/pregnancy-guidelines>.
18. Rozen Eisenberg I, Campbell JI, Clarke D, et al. Practice variability in uptake and implementation of new U.S. DHHS Guidelines for Feeding of HIV-Exposed Infants. *J Pediatric Infect Dis Soc*. 2025;14(1):pia133. Available at: <https://pubmed.ncbi.nlm.nih.gov/39726301>.
19. Ikeri K, Joshi S, Quinones Cardona V, et al. Adoption of the Revised DHHS Guidelines on Breastmilk Feeding and HIV in the United States: Clinical Practices and Barriers. *Open Forum Infect Dis*. 2025;12(10):ofaf607. Available at: <https://pubmed.ncbi.nlm.nih.gov/41103784>.
20. Kasadha B, Hinton L, Tariq S, et al. How women living with HIV in the UK manage infant-feeding decisions and vertical transmission risk - a qualitative study. *BMC Public Health*. 2024;24(1):2130. Available at: <https://pubmed.ncbi.nlm.nih.gov/39107773>.
21. Chaparro AI, Formul D, Vasquez S, et al. Breastfeeding in women with HIV infection: A qualitative study of barriers and facilitators. *PLoS One*. 2024;19(7):e0303788. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39058709>.
22. Fernandes G, Chappell E, Goetghebuer T, et al. HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey. *HIV Med*. 2025;26(2):207-217. Available at: <https://pubmed.ncbi.nlm.nih.gov/39444189>.
23. Moseholm E, Aho I, Mellgren A, et al. Infant feeding knowledge among women living with HIV and their interaction with healthcare providers in a high-income setting: a longitudinal mixed methods study. *Int Breastfeed J*. 2024;19(1):71. Available at: <https://pubmed.ncbi.nlm.nih.gov/39394155>.
24. Keane A, Lyons F, Aebi-Popp K, et al. Guidelines and practice of breastfeeding in women living with HIV-Results from the European INSURE survey. *HIV Med*. 2024;25(3):391-397. Available at: <https://pubmed.ncbi.nlm.nih.gov/38031396>.
25. Haberl L, Audebert F, Feiterna-Sperling C, et al. Not recommended, but done: breastfeeding with HIV in Germany. *AIDS Patient Care STDS*. 2021;35(2):33-38. Available at: <https://pubmed.ncbi.nlm.nih.gov/33571048>.

26. Weiss F, von Both U, Rack-Hoch A, et al. Brief report: HIV-positive and breastfeeding in high-income settings: 5-year experience from a perinatal center in Germany. *J Acquir Immune Defic Syndr*. 2022;91(4):364-367. Available at: <https://pubmed.ncbi.nlm.nih.gov/35944107>.
27. Prestileo T, Adriana S, Lorenza DM, Argo A. From undetectable equals untransmittable (U=U) to breastfeeding: is the jump short? *Infect Dis Rep*. 2022;14(2):220-227. Available at: <https://pubmed.ncbi.nlm.nih.gov/35447879>.
28. Abuogi L, Smith C, Kinzie K, et al. Development and implementation of an interdisciplinary model for the management of breastfeeding in women with HIV in the United States: experience from the Children's Hospital Colorado Immunodeficiency Program. *J Acquir Immune Defic Syndr*. 2023;93(5):395-402. Available at: <https://pubmed.ncbi.nlm.nih.gov/37104739>.
29. Koay WLA, Rakhmanina NY. Supporting mothers living with HIV in the United States who choose to breastfeed. *J Pediatric Infect Dis Soc*. 2022;11(5):239. Available at: <https://pubmed.ncbi.nlm.nih.gov/35238385>.
30. Levison J, McKinney J, Duque A, et al. Breastfeeding among people with human immunodeficiency virus in North America: a multisite study. *Clin Infect Dis*. 2023. Available at: <https://pubmed.ncbi.nlm.nih.gov/37078712>.
31. Yusuf HE, Knott-Grasso MA, Anderson J, et al. Erratum to: experience and outcomes of breastfed infants of women living with HIV in the United States: findings from a single center breastfeeding support initiative. *J Pediatric Infect Dis Soc*. 2022;11(5):240. Available at: <https://pubmed.ncbi.nlm.nih.gov/35285911>.
32. Boyce TG, Havens PL, Henderson SL, Vicetti Miguel CP. From guidelines to practice: a programmatic model for implementation of the updated infant feeding recommendations for people living with HIV. *J Pediatric Infect Dis Soc*. 2024;13(7):381-385. Available at: <https://pubmed.ncbi.nlm.nih.gov/38824437>.
33. Lazenby GB, Sundstrom B, Momplaisir FM, et al. Attitudes on breast feeding among persons with HIV who have given birth and their perceptions of coercion during counseling on safe infant feeding practices. *AIDS Care*. 2023;35(12):1852-1862. Available at: <https://pubmed.ncbi.nlm.nih.gov/36435965>.
34. McKinney J, Mirani G, Levison J. Providers have a responsibility to discuss options for infant feeding with pregnant people with human immunodeficiency virus in high-income countries. *Clin Infect Dis*. 2023;76(3):535-539. Available at: <https://pubmed.ncbi.nlm.nih.gov/36097892>.
35. Powell AM, Knott-Grasso MA, Anderson J, et al. Infant feeding for people living with HIV in high resource settings: a multi-disciplinary approach with best practices to maximise risk reduction. *Lancet Reg Health Am*. 2023;22:100509. Available at: <https://pubmed.ncbi.nlm.nih.gov/37287494>.
36. Lai A, Young ES, Kohrman H, et al. Tilting the scale: current provider perspectives and practices on breastfeeding with HIV in the United States. *AIDS Patient Care STDS*. 2023;37(2):84-94. Available at: <https://pubmed.ncbi.nlm.nih.gov/36787411>.
37. Putnam-Hornstein E, Ahn E, Prindle J, et al. Cumulative rates of child protection involvement and terminations of parental rights in a California birth cohort, 1999-2017. *Am J Public Health*. 2021;111(6):1157-1163. Available at: <https://pubmed.ncbi.nlm.nih.gov/33856882>.

38. Roberts D. The color of child welfare. 2002.
39. Wall-Wieler E, Roos LL, Nickel NC, et al. Mortality among mothers whose children were taken into care by child protection services: a discordant sibling analysis. *Am J Epidemiol*. 2018;187(6):1182-1188. Available at: <https://pubmed.ncbi.nlm.nih.gov/29617918>.
40. Oberhelman-Eaton S, Chang A, Gonzalez C, et al. Initiation of gender-affirming testosterone therapy in a lactating transgender man. *J Hum Lact*. 2022;38(2):339-343. Available at: <https://pubmed.ncbi.nlm.nih.gov/34490813>.
41. Chaparro AI, Formul D, Vasquez S, et al. Breastfeeding in women with HIV infection: A qualitative study of barriers and facilitators. *PLoS One*. 2024;19(7):e0303788. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39058709>.
42. Pagano-Therrien J, Griswold MK, Amoah RK. “Go with the flow”: a qualitative description of infant feeding experiences among women with HIV in the United States. *J Assoc Nurses AIDS Care*. 2023;34(4):376-388. Available at: <https://pubmed.ncbi.nlm.nih.gov/37199426>.
43. The Well Project. Overview of Infant Feeding Options for Parents Living with HIV. 2022. Available at: <https://www.thewellproject.org/hiv-information/overview-infant-feeding-options-parents-living-hiv>
44. Meek JY, Noble L. Section on Breastfeeding. Policy statement: breastfeeding and the use of human milk. *Pediatrics*. 2022;150(1):e2022057988. Available at: <https://pubmed.ncbi.nlm.nih.gov/35921640>.
45. Zhu QY, Huang DS, Lv JD, et al. Prevalence of perinatal depression among HIV-positive women: a systematic review and meta-analysis. *BMC Psychiatry*. 2019;19(1):330. Available at: <https://pubmed.ncbi.nlm.nih.gov/31666033>.
46. Yusuf HE, Knott-Grasso MA, Anderson J, et al. Experience and outcomes of breastfed infants of women living with HIV in the United states: findings from a single-center breastfeeding support initiative. *J Pediatric Infect Dis Soc*. 2022;11(1):24-27. Available at: <https://pubmed.ncbi.nlm.nih.gov/34888664>.
47. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. *Lancet*. 2007;369(9567):1107-1116. Available at: <https://pubmed.ncbi.nlm.nih.gov/17398310>.
48. Coutoudis A, Pillay K, Spooner E, et al. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African vitamin A study group. *Lancet*. 1999;354(9177):471-476. Available at: <https://pubmed.ncbi.nlm.nih.gov/10465172>.
49. Becquet R, Bland R, Leroy V, et al. Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts. *PLoS One*. 2009;4(10):e7397. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19834601>.
50. Rutagwera DG, Molès JP, Kankasa C, et al. Recurrent severe subclinical mastitis and the risk of HIV transmission through breastfeeding. *Front Immunol*. 2022;13:822076. Available at: <https://pubmed.ncbi.nlm.nih.gov/35309352>.

51. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. *N Engl J Med*. 2008;359(2):130-141. Available at: <https://pubmed.ncbi.nlm.nih.gov/18525036>.
52. Thea DM, Aldrovandi G, Kankasa C, et al. Post-weaning breast milk HIV-1 viral load, blood prolactin levels and breast milk volume. *AIDS*. 2006;20(11):1539-1547. Available at: <https://pubmed.ncbi.nlm.nih.gov/16847409>.
53. Kuhn L, Kim HY, Walter J, et al. HIV-1 concentrations in human breast milk before and after weaning. *Sci Transl Med*. 2013;5(181):181ra151. Available at: <https://pubmed.ncbi.nlm.nih.gov/23596203>.
54. Israel-Ballard K, Chantry C, Dewey K, et al. Viral, nutritional, and bacterial safety of flash-heated and pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study. *J Acquir Immune Defic Syndr*. 2005;40(2):175-181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16186735>.
55. Israel-Ballard K, Donovan R, Chantry C, et al. Flash-heat inactivation of HIV-1 in human milk: a potential method to reduce postnatal transmission in developing countries. *J Acquir Immune Defic Syndr*. 2007;45(3):318-323. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17514015>.
56. Mitchell KB, Johnson HM, Rodríguez JM, et al. Academy of Breastfeeding Medicine Clinical Protocol #36: The Mastitis Spectrum, revised 2022. *Breastfeed Med*. 2022;17(5):360-376. Available at: <https://pubmed.ncbi.nlm.nih.gov/35576513>.
57. Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother-child transmission of HIV-1. *AIDS*. 2000;14(16):2535-2541. Available at: <https://pubmed.ncbi.nlm.nih.gov/11101065>.
58. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. *J Infect Dis*. 1999;180(1):93-98. Available at: <https://pubmed.ncbi.nlm.nih.gov/10353866>.
59. Semrau K, Kuhn L, Brooks DR, et al. Dynamics of breast milk HIV-1 RNA with unilateral mastitis or abscess. *J Acquir Immune Defic Syndr*. 2013;62(3):348-355. Available at: <https://pubmed.ncbi.nlm.nih.gov/23202812>.
60. Lunney KM, Iliff P, Mutasa K, et al. Associations between breast milk viral load, mastitis, exclusive breast-feeding, and postnatal transmission of HIV. *Clin Infect Dis*. 2010;50(5):762-769. Available at: <https://pubmed.ncbi.nlm.nih.gov/20121424>.
61. Cherkos AS, LaCourse SM, Kinuthia J, et al. Maternal breastfeeding and education impact infant growth and development more than in-utero HIV/antiretroviral therapy exposure in context of universal antiretroviral therapy. *AIDS*. 2024;38(4):537-546. Available at: <https://pubmed.ncbi.nlm.nih.gov/37967230>.
62. Gross MS, Taylor HA, Tomori C, Coleman JS. Breastfeeding with HIV: an evidence-based case for new policy. *J Law Med Ethics*. 2019;47(1):152-160. Available at: <https://pubmed.ncbi.nlm.nih.gov/30994076>.
63. Hinson TD, Skinner AC, Spatz DL. Subject matter experts identify health equity concerns in breastfeeding for African American women. *J Perinat Neonatal Nurs*. 2021;35(2):160-168. Available at: <https://pubmed.ncbi.nlm.nih.gov/33346570>.

64. Murray A, Hall A, Weaver J, Kremer F. Methods for estimating locations of housing units served by private domestic wells in the United States applied to 2010. *J Am Water Resour Assoc*. 2021;57(5):1-16. Available at: <https://pubmed.ncbi.nlm.nih.gov/34987281>.
65. Levison J, Weber S, Cohan D. Breastfeeding and HIV-infected women in the United States: harm reduction counseling strategies. *Clin Infect Dis*. 2014;59(2):304-309. Available at: <https://pubmed.ncbi.nlm.nih.gov/24771330>.
66. Greene S, Ion A, Elston D, et al. “Why aren't you breastfeeding?”: how mothers living with HIV talk about infant feeding in a “breast is best” world. *Health Care Women Int*. 2015;36(8):883-901. Available at: <https://pubmed.ncbi.nlm.nih.gov/24527767>.
67. Tariq S, Elford J, Tookey P, et al. “It pains me because as a woman you have to breastfeed your baby”: decision-making about infant feeding among African women living with HIV in the UK. *Sex Transm Infect*. 2016;92(5):331-336. Available at: <https://pubmed.ncbi.nlm.nih.gov/26757986>.
68. Freeman-Romilly N, Nyatsanza F, Namiba A, Lyall H. Moving closer to what women want? A review of breastfeeding and women living with HIV in the UK and high-income countries. *HIV Med*. 2020;21(1):1-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/31825556>.
69. Etowa J, Babatunde S, Hannan J, et al. Motherhood among Black women living with HIV: A “north-south” comparison of sociocultural and psychological factors. *Health Care Women Int*. 2021;42(3):304-322. Available at: <https://pubmed.ncbi.nlm.nih.gov/33600277>.
70. Etowa J, Nare H, Kakuru DM, Etowa EB. Psychosocial experiences of HIV-positive women of African descent in the cultural context of infant feeding: a three-country comparative analyses. *Int J Environ Res Public Health*. 2020;17(19):7150. Available at: <https://pubmed.ncbi.nlm.nih.gov/33003622>.
71. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. *JAMA*. 2000;283(9):1167-1174. Available at: <https://pubmed.ncbi.nlm.nih.gov/10703779>.
72. World Health Organization. HIV Transmission through breastfeeding: a review of available evidence: 2007 update. 2008. Available at: http://apps.who.int/iris/bitstream/10665/43879/1/9789241596596_eng.pdf
73. Weinberg GA, Nachman S. Breastfeeding by women living with HIV in the United States: are the risks truly manageable? *J Pediatric Infect Dis Soc*. 2022;11(3):92-93. Available at: <https://pubmed.ncbi.nlm.nih.gov/34939650>.
74. Waitt C, Low N, Van de Perre P, et al. Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings. *Lancet HIV*. 2018;5(9):e531-e536. Available at: <https://pubmed.ncbi.nlm.nih.gov/29960731>.
75. Flynn PM, Taha TE, Cababasay M, et al. Association of maternal viral load and CD4 count with perinatal HIV-1 transmission risk during breastfeeding in the PROMISE postpartum component. *J Acquir Immune Defic Syndr*. 2021;88(2):206-213. Available at: <https://pubmed.ncbi.nlm.nih.gov/34108383>.

76. Davis NL, Miller WC, Hudgens MG, et al. Maternal and breastmilk viral load: impacts of adherence on peripartum HIV infections averted-the Breastfeeding, Antiretrovirals, and Nutrition Study. *J Acquir Immune Defic Syndr*. 2016;73(5):572-580. Available at: <https://pubmed.ncbi.nlm.nih.gov/27846071>.
77. Osegueda A, Baquero L, Casanova AP, et al. HIV reservoir landscape in breast milk from long-term virally suppressed individuals. *Ann Intern Med*. 2024;177(11):1595-1598. Available at: <https://pubmed.ncbi.nlm.nih.gov/39374525>.
78. Dugdale CM, Ufio O, Giardina J, et al. Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis. *Lancet*. 2025;406(10501):349-357. Available at: <https://pubmed.ncbi.nlm.nih.gov/40652949>.
79. Bispo S, Chikhungu L, Rollins N, et al. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. *J Int AIDS Soc*. 2017;20(1):21251. Available at: <https://pubmed.ncbi.nlm.nih.gov/28362072>.
80. White AB, Mirjahangir JF, Horvath H, et al. Antiretroviral interventions for preventing breast milk transmission of HIV. *Cochrane Database Syst Rev*. 2014;2014(10):CD011323. Available at: <https://pubmed.ncbi.nlm.nih.gov/25280769>.
81. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. *N Engl J Med*. 2010;362(24):2271-2281. Available at: <https://pubmed.ncbi.nlm.nih.gov/20554982>.
82. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2012;379(9812):221-228. Available at: <https://pubmed.ncbi.nlm.nih.gov/22196945>.
83. Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. *Lancet*. 2016;387(10018):566-573. Available at: <https://pubmed.ncbi.nlm.nih.gov/26603917>.
84. Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. *Lancet Infect Dis*. 2011;11(3):171-180. Available at: <https://pubmed.ncbi.nlm.nih.gov/21237718>.
85. Boyce CL, Sils T, Ko D, et al. Maternal human immunodeficiency virus (HIV) drug resistance Is associated with vertical transmission and Is prevalent in infected infants. *Clin Infect Dis*. 2022;74(11):2001-2009. Available at: <https://pubmed.ncbi.nlm.nih.gov/34467974>.
86. Luoga E, Vanobberghen F, Bircher R, et al. Brief report: no HIV transmission from virally suppressed mothers during breastfeeding in rural Tanzania. *J Acquir Immune Defic Syndr*. 2018;79(1):e17-e20. Available at: <https://pubmed.ncbi.nlm.nih.gov/29781882>.
87. Zijenah LS, Bandason T, Bara W, et al. Impact of Option B(+) combination antiretroviral therapy on mother-to-child transmission of HIV-1, maternal and infant virologic responses to combination antiretroviral therapy, and maternal and infant mortality rates: a 24-month prospective follow-up study at a primary health care clinic, in Harare, Zimbabwe. *AIDS Patient Care STDS*. 2022;36(4):145-152. Available at: <https://pubmed.ncbi.nlm.nih.gov/35438521>.

88. Giuliano M, Andreotti M, Liotta G, et al. Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. *PLoS One*. 2013;8(7):e68950. Available at: <https://pubmed.ncbi.nlm.nih.gov/23894379>.
89. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. *N Engl J Med*. 2010;362(24):2282-2294. Available at: <https://pubmed.ncbi.nlm.nih.gov/20554983>.
90. Bishop MD, Korutaro V, Boyce CL, et al. Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. *J Acquir Immune Defic Syndr*. 2024;96(4):385-392. Available at: <https://pubmed.ncbi.nlm.nih.gov/39175843>.
91. Chinula L, Ziemba L, Brummel S, et al. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. *Lancet HIV*. 2023;10(6):e363-e374. Available at: <https://pubmed.ncbi.nlm.nih.gov/37167996>.
92. Volpe LJ, Powis KM, Legbedze J, et al. A counseling and monitoring approach for supporting breastfeeding women living with HIV in Botswana. *J Acquir Immune Defic Syndr*. 2022;89(2):e16. Available at: <https://pubmed.ncbi.nlm.nih.gov/34723927>.
93. Waitt C, Olagunju A, Nakalema S, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother–infant pairs. *J Antimicrob Chemother*. 2018;73(4):1013-1019. Available at: <https://pubmed.ncbi.nlm.nih.gov/29309634>.
94. Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. *PLoS Med*. 2016;13(9):e1002132. Available at: <https://pubmed.ncbi.nlm.nih.gov/27676257>.
95. Palombi L, Pirillo MF, Marchei E, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. *J Antimicrob Chemother*. 2016;71(4):1027-1030. Available at: <https://pubmed.ncbi.nlm.nih.gov/26679247>.
96. Davis NL, Corbett A, Kaullen J, et al. Antiretroviral drug concentrations in breastmilk, maternal HIV viral load, and HIV transmission to the infant: results from the BAN Study. *J Acquir Immune Defic Syndr*. 2019;80(4):467-473. Available at: <https://pubmed.ncbi.nlm.nih.gov/30570527>.
97. Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DOLPHIN-1 study). *PLoS Med*. 2019;16(9):e1002895. Available at: <https://pubmed.ncbi.nlm.nih.gov/31539371>.
98. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. *AIDS*. 2017;31(2):213-232. Available at: <https://pubmed.ncbi.nlm.nih.gov/27831952>.
99. Stranix-Chibanda L, Tierney C, Sebikari D, et al. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. *PLoS One*. 2021;16(2):e0246272. Available at: <https://pubmed.ncbi.nlm.nih.gov/33544759>.

100. Nabwire F, Prentice A, Hamill MM, et al. Changes in bone mineral density during and after lactation in Ugandan women with HIV on tenofovir-based antiretroviral therapy. *J Bone Miner Res.* 2020;35(11):2091-2102. Available at: <https://pubmed.ncbi.nlm.nih.gov/32573842>.